Zydus Lifesciences Gets Phase III Trial Approval for Desidustat in Sickle Cell Disease.
$ZYDUSLIFE has received approval to initiate the Phase III clinical trial of its oral drug Desidustat for treating Sickle Cell Disease patients. The trial will be conducted in collaboration with the Indian Council of Medical Research (ICMR…

















